Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Revenue (2016 - 2025)

Historic Revenue for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $29.7 million.

  • Regenxbio's Revenue rose 2287.89% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.3 million, marking a year-over-year increase of 9130.05%. This contributed to the annual value of $83.3 million for FY2024, which is 766.16% down from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Revenue is $29.7 million, which was up 2287.89% from $21.4 million recorded in Q2 2025.
  • Regenxbio's 5-year Revenue high stood at $398.7 million for Q4 2021, and its period low was $15.6 million during Q1 2024.
  • Over the past 5 years, Regenxbio's median Revenue value was $22.3 million (recorded in 2024), while the average stood at $47.2 million.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 175896.48% in 2021, then crashed by 9213.73% in 2022.
  • Regenxbio's Revenue (Quarter) stood at $398.7 million in 2021, then plummeted by 92.14% to $31.3 million in 2022, then dropped by 29.13% to $22.2 million in 2023, then fell by 4.5% to $21.2 million in 2024, then surged by 40.16% to $29.7 million in 2025.
  • Its Revenue stands at $29.7 million for Q3 2025, versus $21.4 million for Q2 2025 and $89.0 million for Q1 2025.